SARS-CoV-2 neutralizing antibody response in vaccinated and non-vaccinated hospital healthcare workers with or without history of infection – ScienceDirect

Between March 2021 and February 2022, a study in Switzerland investigated the dynamics of SARS-CoV-2 neutralizing antibodies in 903 healthcare workers. They used a surrogate assay to measure neutralization against the virus’s spike protein and its variants. Results strongly supported the booster dose strategy.

While additional boosters within three to six months after a third immunization event may not greatly enhance immunity, monitoring antibody decline beyond this window is crucial on an individual basis, considering new variants.

The effectiveness of prior neutralizing antibodies against emerging variants is uncertain, highlighted by reduced immunity to recent Omicron variants. Incorporating newly appearing variants into booster vaccines could help address the challenge of sustaining effective long-term immunity.

Recently, the U.S. Food and Drug Administration (FDA) mandated XBB.1.5-specific COVID-19 vaccines for the upcoming season. NAB-Sure XBB.1.5 variant NAb test kit will be an effective tool for assessing populations’ immune status and vaccines’ efficacy and can effectively be run on DBS samples.

Wild Type, Omicron BA.4/5, and BQ.1.1 variants are also available.